UBS Maintains a 'Neutral' on InterMune (ITMN); Shionogi Moves Ahead on Royalty Demands

July 9, 2012 10:50 AM EDT Send to a Friend
Get Alerts ITMN Hot Sheet
Price: $9.85 +0.20%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 30
Trade ITMN Now!
UBS maintains a 'Neutral' on InterMune Inc. (NASDAQ: ITMN) price target of $13.50.

Analyst, Matthew Harrison, noted the 8-K filed last Friday, regarding a compliant filed against the company from Shionogi & Co. which alleges InterMune breached an agreement between InterMune and Shionogi governing the exchange and use of certain documents and information relating to the parties' respective clinical trials of pirfenidone...The compliant also alleges that ITMN has failed to pay royalties for sales of pirfenidone (Esbriet) in the EU.

For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.

Shares of InterMune Inc. closed at $11.79 yesterday, with a 52 week range of $9.66-$37.45.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Litigation

Related Entities

UBS

Add Your Comment